HOME > TOP STORIES
TOP STORIES
-
TRENDS Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
-
BUSINESS Amylyx Gears Up to Bring New ALS Drug to Japan Market: Country Chief
December 27, 2023
-
REGULATORY Japan Officially Drops Japanese PI Requirement before Global Trial Entry
December 26, 2023
-
REGULATORY (Update) Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 25, 2023
-
BUSINESS Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 22, 2023
-
ORGANIZATION Reform Package Is “First Step” towards Global Standard, but More Work Remains: JPMA
December 22, 2023
-
REGULATORY Japan to Roll Out New LLP Coverage Rule in October; 18 Billion Yen Saving Eyed for FY2024
December 21, 2023
-
REGULATORY Japan to Cut Drug Prices by 0.97% on Healthcare Cost Basis in FY2024
December 20, 2023
-
REGULATORY Gist of FY2024 Drug Pricing Reform
December 20, 2023
-
COMMENTARY Women’s Health Drugs on a Roll, Further Growth Expected as Public Awareness Rises
December 19, 2023
-
REGULATORY Chuikyo Split on Copay Rate under Elective Care Scheme; Political Decision Likely over 1/2 or 1/4
December 18, 2023
-
BUSINESS Cheplapharm Initiates LLP Acquisitions in Japan, Eyes 10 Asset Takeovers in 2024: Local Head
December 15, 2023
-
REGULATORY Japan OKs FY2024 Tax Reform Outline, “Innovation Box” Scheme Etched
December 15, 2023
-
REGULATORY Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing
December 14, 2023
-
REGULATORY Shionogi’s Novel Antibiotic Fetroja Gets Fast-Track Listing for Dec. 20
December 14, 2023
-
REGULATORY Leqembi OK’ed for Listing on Dec. 20; Peak Sales Put at 98.6 Billion Yen
December 13, 2023
-
BUSINESS Sobi Eyes Japan Approval of 4 Rare Disease Drugs in 5 Years: Local Chief
December 12, 2023
-
REGULATORY Japan Reform Minister Calls for Roadmap to Eliminate “Switch Lags” in 3 Years
December 12, 2023
-
REGULATORY Japan Panel OKs Basic Plan for Elective Care Scheme for LLPs; 900 APIs Targeted
December 11, 2023
-
REGULATORY Will R&D Tax Credit Be Scaled Back with “Innovation Box” Rollout? Political Settlement Likely
December 8, 2023
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
